Literature DB >> 10200564

Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells.

T E Hedlund1, S J Meech, S Srikanth, A S Kraft, G J Miller, J B Schaack, R C Duke.   

Abstract

Several laboratories have reported on the apoptotic potentials of human prostate cancer (PC) cell lines in response to crosslinking of Fas (CD95/APO-1) with agonistic anti-Fas antibodies. We have re-evaluated the apoptotic potentials of seven human PC cell lines using the natural Fas ligand (FasL) in place of agonistic antibody. First, PC cell lines were tested in a standard cytotoxicity assay with a transfected cell line that stably expresses human FasL. Next, we developed an adenoviral expression system employing 293 cells that stably express crmA, a poxvirus inhibitor of apoptosis, to analyze the effects of FasL when expressed internally by the PC cell lines. Our data suggest that the apoptotic potentials of these cell lines were greatly underestimated in previous studies utilizing agonistic anti-Fas antibodies. Lastly, adenoviral-mediated expression of FasL prevented growth and induced regression of two human PC cell lines in immunodeficient mice. These preliminary in vivo results suggest a potential use for adenovirus encoding FasL as a gene therapy for PC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10200564     DOI: 10.1038/sj.cdd.4400477

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  6 in total

1.  Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment.

Authors:  Jaime F Modiano; Beth A Lindborg; Ron T McElmurry; Mitzi Lewellen; Colleen L Forster; Edward A Zamora; Jerome Schaack; Donald Bellgrau; Timothy D O'Brien; Jakub Tolar
Journal:  Cancer Immunol Immunother       Date:  2015-08-07       Impact factor: 6.968

2.  An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy.

Authors:  Isaac Sipo; Almudena Hurtado Picó; Xiaomin Wang; Jürgen Eberle; Iver Petersen; Stefan Weger; Wolfgang Poller; Henry Fechner
Journal:  J Mol Med (Berl)       Date:  2005-12-31       Impact factor: 4.599

3.  Adenoviral-mediated pHyde gene transfer and cisplatin additively inhibit human prostate cancer growth by enhancing apoptosis.

Authors:  Yi Lu; Xiongwen Zhang; Ben Beheshti; Jun Zhang
Journal:  Prostate       Date:  2009-02-15       Impact factor: 4.104

Review 4.  Targeted nonviral gene therapy in prostate cancer.

Authors:  Najla Altwaijry; Sukrut Somani; Christine Dufès
Journal:  Int J Nanomedicine       Date:  2018-09-25

Review 5.  Death receptors as targets for anti-cancer therapy.

Authors:  Kerstin Papenfuss; Stefanie M Cordier; Henning Walczak
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

6.  Progress in Adaptive Immunotherapy for Cancer in Companion Animals: Success on the Path to a Cure.

Authors:  Katie L Anderson; Jaime F Modiano
Journal:  Vet Sci       Date:  2015-10-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.